3SBio (HK:1530) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
3SBio Inc.’s subsidiary, Sunshine Mandi, has inked a lucrative cooperation agreement with Hybio Pharmaceutical for the joint development and exclusive supply of Semaglutide Injection, a weight management product. Under the deal, Sunshine Mandi is set to make milestone payments up to RMB 270 million to Hybio, including preclinical results, exclusive purchase prices, and profit-based royalties. The partnership aims to market and commercialize the product, with Sunshine Mandi holding exclusive marketing rights in certain regions and Hybio handling production.
For further insights into HK:1530 stock, check out TipRanks’ Stock Analysis page.
